Genom Company, 'GEN-001' Gastric Cancer Phase 2 Data Selected for ASCO GI Abstract

Genome & Company, a drug development company, announced on the 15th that it will present key data from the Phase 2 clinical trial of the microbiome immuno-oncology drug ‘GEN-001’ targeting gastric cancer at the ‘American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2024)’ to be held in January next year.

Bae Jisoo, CEO of Genome & Company. [Photo by Lee Chunhee].jpg

This presentation will include data from the Phase 2 clinical trial of GEN-001 targeting gastric cancer collected up to the time of the ASCO GI presentation. Recruitment of the target 42 patients has been completed, and key data on safety and efficacy will be disclosed.

GEN-001 is a microbiome-based immuno-oncology drug currently undergoing a Phase 2 clinical trial for gastric cancer in combination with Bavencio (active ingredient Avelumab) from Merck Germany. Since developing new treatments for gastric cancer patients who have failed second-line or later standard therapies is crucial, the goal of this trial is to demonstrate superior efficacy that overcomes the limitations of existing immuno-oncology drugs.

Jisoo Bae, CEO of Genome & Company, stated, “The ASCO GI presentation is highly significant in proving the anticancer efficacy of GEN-001,” and added, “In the unstable financial market environment and during a prolonged downturn in the bio industry, we hope this presentation will serve as a positive signal.”

This content was produced with the assistance of AI translation services.